Matti Karvonen will help expand the company's clinical programmes

Faron Pharmaceuticals has appointed Matti Karvonen as its new Medical Director. Dr. Karvonen will be responsible for overseeing Faron's drug development strategy and will play a central role in expanding the clinical programmes of Traumakine and Clevegen. 

Dr. Markku Jalkanen, CEO of Faron said: "We are delighted to welcome Dr. Karvonen to our ambitious Executive Management Team. His appointment comes at an important time for Faron as we expand our clinical activities. Our lead drug candidate Traumakine, for the treatment of Acute Respiratory Distress Syndrome (ARDS) is now in a pan-European Phase III INTEREST trial, while clinical development for Clevegen, our novel cancer immunotherapy drug candidate is under active planning. Dr. Karvonen's experience in taking drugs through development programmes will provide an invaluable insight into the needsof both ARDS and cancer patients." 

Dr. Karvonen has a background in clinical neurology with a deep medical experience in many international pharmaceutical organisations, including Roche, Biogen Idec and Novartis, and has participated in many clinical programmes, most recently in the pan-European launch of a new neurological drug. In the early part of his career Dr. Karvonen held several research positions and he has also co-founded several commercial medical organisations.